Zevra Therapeutics (NASDAQ:ZVRA) Share Price Breaks Above 200-Day Moving Average – What’s Next?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s stock price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.76 and traded as high as $11.19. Zevra Therapeutics shares last traded at $11.17, with a volume of 2,064,533 shares traded.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 2026 revenue rose 45% year over year to $37.8 million, including $34.0 million from MIPLYFFA. Earnings also beat analyst estimates, and the company marked a fourth consecutive quarterly earnings beat. Zevra Q3 financial results and corporate update Zevra beats Q3 estimates for fourth straight quarter
• Positive Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, a potential future growth opportunity. Zevra anticipates filing MIPLYFFA sNDA in Q1 2027
• Neutral Sentiment: A European CHMP opinion on MIPLYFFA remains expected in Q4; the regulatory outcome is still pending. Regulatory timeline update

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ZVRA. BTIG Research reduced their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Thursday, August 20th. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $27.14.

Zevra Therapeutics Stock Up 8.9%

The stock has a 50-day moving average of $11.10 and a 200-day moving average of $10.76. The company has a market cap of $663.27 million, a PE ratio of 9.39 and a beta of 1.01.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 57.91%. The company had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. Research analysts expect that Zevra Therapeutics, Inc. will post 0.72 EPS for the current year.

Insider Buying and Selling

In related news, CEO Neil McFarlane sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares of the company’s stock, valued at approximately $20,250. This represents a 87.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC bought a new position in Zevra Therapeutics during the 1st quarter valued at about $11,184,000. Integrity Alliance LLC. bought a new position in Zevra Therapeutics in the 3rd quarter worth approximately $10,292,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Finally, Mystic Asset Management Inc. increased its holdings in shares of Zevra Therapeutics by 0.9% in the 3rd quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock worth $3,899,000 after buying an additional 3,270 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.